J&J Bullish On OTC Drug Pricing, Consumer Regard For Its Brands
This article was originally published in The Tan Sheet
Brand strength, not price cuts, drives J&J OTC product sales, says Worldwide Group Chairwoman Sandra Peterson. The firm has returned 80% of its recalled brands to store shelves and will restart Tylenol Arthritis distribution later this year, leaving one “substantive” product to re-launch.
Register for our free email digests: